| scholarly article | Q13442814 |
| review article | Q7318358 |
| P2093 | author name string | Barbara Wroblewska | |
| Joseph H Neale | |||
| Tomasz Bzdega | |||
| Rafal T Olszewski | |||
| Laura M Gehl | |||
| P2860 | cites work | Neuroprotection mediated by glial group-II metabotropic glutamate receptors requires the activation of the MAP kinase and the phosphatidylinositol-3-kinase pathways. | Q43694465 |
| P433 | issue | 9 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | schizophrenia | Q41112 |
| neurotransmitter | Q162657 | ||
| diabetic neuropathy | Q2046550 | ||
| amyotrophic lateral sclerosis | Q206901 | ||
| P304 | page(s) | 477-84 | |
| P577 | publication date | 2005-09-01 | |
| P1433 | published in | Trends in Pharmacological Sciences | Q2451474 |
| P1476 | title | The neurotransmitter N-acetylaspartylglutamate in models of pain, ALS, diabetic neuropathy, CNS injury and schizophrenia | |
| P478 | volume | 26 |
| Q27643940 | A high-resolution structure of ligand-free human glutamate carboxypeptidase II |
| Q38887993 | A role for the locus coeruleus in the analgesic efficacy of N-acetylaspartylglutamate peptidase (GCPII) inhibitors ZJ43 and 2-PMPA. |
| Q30465259 | Advances in understanding the peptide neurotransmitter NAAG and appearance of a new member of the NAAG neuropeptide family |
| Q27339223 | Aspartoacylase-lacZ knockin mice: an engineered model of Canavan disease |
| Q41871074 | Bioanalytical method for evaluating the pharmacokinetics of the GCP-II inhibitor 2-phosphonomethyl pentanedioic acid (2-PMPA). |
| Q27658096 | Bioisosterism of urea-based GCPII inhibitors: Synthesis and structure–activity relationship studies |
| Q48100710 | Differential regional N-acetylaspartate deficits in postmortem brain in schizophrenia, bipolar disorder and major depressive disorder |
| Q36527334 | Dysregulation of glutamate carboxypeptidase II in psychiatric disease. |
| Q36052391 | Effects of N-acetylaspartylglutamate (NAAG) peptidase inhibition on release of glutamate and dopamine in prefrontal cortex and nucleus accumbens in phencyclidine model of schizophrenia |
| Q27676272 | Efficient and versatile one-step affinity purification of in vivo biotinylated proteins: Expression, characterization and structure analysis of recombinant human glutamate carboxypeptidase II |
| Q42065018 | Endogenous N-acetylaspartylglutamate (NAAG) inhibits synaptic plasticity/transmission in the amygdala in a mouse inflammatory pain model. |
| Q37234095 | Endogenous interleukin-1β in neuropathic rats enhances glutamate release from the primary afferents in the spinal dorsal horn through coupling with presynaptic N-methyl-D-aspartic acid receptors |
| Q50135884 | Extracellular N-acetylaspartylglutamate released in the nucleus accumbens modulates the pain sensation: Analysis using a microdialysis/mass spectrometry integrated system |
| Q41976143 | FOLH1/GCPII is elevated in IBD patients, and its inhibition ameliorates murine IBD abnormalities |
| Q43227545 | GCP II inhibition rescues neurons from gp120IIIB-induced neurotoxicity |
| Q35693294 | Glutamate carboxypeptidase II (GCPII) inhibitor displays anti-glutamate and anti-cocaine effects in an invertebrate assay |
| Q40475257 | Glutamate carboxypeptidase II is not an amyloid peptide-degrading enzyme. |
| Q41911926 | Glutamate carboxypeptidase activity in human skin biopsies as a pharmacodynamic marker for clinical studies |
| Q43274870 | Glutamate carboxypeptidase inhibition reduces the severity of chemotherapy-induced peripheral neurotoxicity in rat. |
| Q57816814 | Group II Metabotropic Glutamate Receptors: Role in Pain Mechanisms and Pain Modulation |
| Q30466262 | Group II mGluR agonist LY354740 and NAAG peptidase inhibitor effects on prepulse inhibition in PCP and D-amphetamine models of schizophrenia. |
| Q36514196 | Immunohistological and electrophysiological evidence that N-acetylaspartylglutamate is a co-transmitter at the vertebrate neuromuscular junction |
| Q33601673 | Inhibition of NAALADase by 2-PMPA attenuates cocaine-induced relapse in rats: a NAAG-mGluR2/3-mediated mechanism |
| Q42397202 | Intracerebroventricular administration of N-acetylaspartylglutamate (NAAG) peptidase inhibitors is analgesic in inflammatory pain |
| Q33757934 | Magnetic resonance spectroscopy of regional brain metabolite markers in FALS mice and the effects of dietary creatine supplementation |
| Q28592468 | Molecular characterization of N-acetylaspartylglutamate synthetase |
| Q41627655 | Mouse glutamate carboxypeptidase II (GCPII) has a similar enzyme activity and inhibition profile but a different tissue distribution to human GCPII. |
| Q99590999 | N-Acetylaspartylglutamate (NAAG) Pretreatment Reduces Hypoxic-Ischemic Brain Damage and Oxidative Stress in Neonatal Rats |
| Q41913170 | N-[N-[(S)-1,3-Dicarboxypropyl]carbamoyl]-4-[18F]fluorobenzyl-L-cysteine, [18F]DCFBC: a new imaging probe for prostate cancer |
| Q37438511 | N-acetylaspartylglutamate (NAAG) inhibits intravenous cocaine self-administration and cocaine-enhanced brain-stimulation reward in rats. |
| Q47341572 | N-acetylaspartylglutamate Inhibits Heroin Self-Administration and Heroin-Seeking Behaviors Induced by Cue or Priming in Rats |
| Q38833017 | N-acetylaspartylglutamate is an agonist at mGluR₃ in vivo and in vitro |
| Q28590380 | N-acetylaspartylglutamate synthetase II synthesizes N-acetylaspartylglutamylglutamate |
| Q38912835 | NAAG Peptidase Inhibitors Act via mGluR3: Animal Models of Memory, Alzheimer's, and Ethanol Intoxication. |
| Q30459203 | NAAG peptidase inhibition in the periaqueductal gray and rostral ventromedial medulla reduces flinching in the formalin model of inflammation |
| Q41512816 | NAAG peptidase inhibitor improves motor function and reduces cognitive dysfunction in a model of TBI with secondary hypoxia |
| Q42285300 | NAAG peptidase inhibitor reduces cellular damage in a model of TBI with secondary hypoxia |
| Q36675499 | NAAG peptidase inhibitors and deletion of NAAG peptidase gene enhance memory in novel object recognition test |
| Q30465008 | NAAG peptidase inhibitors block cognitive deficit induced by MK-801 and motor activation induced by d-amphetamine in animal models of schizophrenia. |
| Q27674033 | Novel Substrate-Based Inhibitors of Human Glutamate Carboxypeptidase II with Enhanced Lipophilicity |
| Q33641563 | Oral administration of the NAALADase inhibitor GPI-5693 attenuates cocaine-induced reinstatement of drug-seeking behavior in rats. |
| Q37270885 | Pathophysiology and treatment of painful diabetic neuropathy. |
| Q30491856 | Phencyclidine and dizocilpine induced behaviors reduced by N-acetylaspartylglutamate peptidase inhibition via metabotropic glutamate receptors |
| Q42742435 | Post-injury administration of NAAG peptidase inhibitor prodrug, PGI-02776, in experimental TBI |
| Q48515881 | Report on the Symposium "Molecular Mechanisms Involved in Neurodegeneration". |
| Q36406289 | Reversible disulfide formation of the glutamate carboxypeptidase II inhibitor E2072 results in prolonged systemic exposures in vivo |
| Q35032387 | The folate hydrolase 1561C>T polymorphism is associated with depressive symptoms in Puerto Rican adults |
| Q34537679 | mGlu2 metabotropic glutamate receptors restrain inflammatory pain and mediate the analgesic activity of dual mGlu2/mGlu3 receptor agonists |
Search more.